Edition:
United Kingdom

People: Aravive Inc (ARAV.OQ)

ARAV.OQ on NASDAQ Stock Exchange Global Select Market

5.86USD
26 Jun 2019
Change (% chg)

$-0.14 (-2.33%)
Prev Close
$6.00
Open
$5.98
Day's High
$5.98
Day's Low
$5.75
Volume
5,488
Avg. Vol
5,571
52-wk High
$13.50
52-wk Low
$3.07

Akkaraju, Srinivas 

Mr. Srinivas Akkaraju, M.D., Ph.D., is an Independent Chairman of the Board of Versartis, Inc. He has served as a member of our board of directors since July 2013. Dr. Akkaraju previously served as a member of our board of directors from February 2011 to February 2013. Dr. Akkaraju is currently a General Partner at Sofinnova Ventures, or Sofinnova, which he joined in April 2013. Prior to joining Sofinnova, Dr. Akkaraju was a Managing Director at New Leaf Venture Partners, or New Leaf from January 2009 to April 2013. From September 2006 to December 2008, Dr. Akkaraju served as a managing director at Panorama Capital, LLC, a private equity firm founded by the former venture capital investment team of J.P. Morgan Partners, LLC, or JPMP, a private equity division of JPMorgan Chase & Co. From April 2001 to September 2006, Dr. Akkaraju was a part of the health care investment team at JPMP, most recently as Partner. Dr. Akkaraju has served on the boards of directors of numerous public and private companies, including Synageva BioPharma Corp., Barrier Therapeutics, Inc. and EyeTech Pharmaceuticals Inc., all of which are or were publicly traded biotechnology companies, and Amarin Corporation plc, a foreign publicly traded biotechnology company, and currently serves on the boards of directors of Intercept Pharmaceuticals, Inc. and Seattle Genetics, Inc. Dr. Akkaraju holds a B.A. in Biochemistry and Computer Science from Rice University and an M.D. and Ph.D. in Immunology from Stanford University School of Medicine.

Basic Compensation

Total Annual Compensation, USD 85,000
Restricted Stock Award, USD 128,593
Long-Term Incentive Plans, USD --
All Other, USD 68,618
Fiscal Year Total, USD 282,211

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --